The Merck Institute antimalarial compound, M5717, is the first plasmodium eEF2 inhibitor to reach clinical development, and is a good example of an orally available dibasic compound as well as an antimalarial with a discrete target identified after traditional phenotypic screening. It was well-tolerated in healthy volunteers and has a [...]
< 1 minute read
Dec. 20, 2021
M5717: the First Plasmodium eEF2 Inhibitor in The Clinic
M5717
oral plasmodium eEF2 inhibitor Ph. I candidate for malaria treatment from phenotypic screen & optimization The Lancet Merck Institute for Pharmacometrics